US strikes $138m deal to ensure enough syringes for COVID-19 vaccine

URLhttps://www.biopharma-reporter.com/Article/2020/05
SourceBiopharma Reporter
Date Published05/13/2020
Author NameBen Hargreaves
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Rapid USA
Parent companyApiject Systems America
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
City reshored to:Stamford
State(s) reshored to:CT
If relevant, work nearshored to:-
Industry(ies):Chemicals, Medical Equipment & Supplies
Product(s) reshoredplastic pre-filled syringes, vaccines
What domestic positive factors made reshoring more attractive?Government Incentives, covid-19
Government Incentive dollar amount:$138 + $456 million
Find Reshoring Articles